Back to Journals » OncoTargets and Therapy » Volume 9

miR-429 functions as a tumor suppressor by targeting FSCN1 in gastric cancer cells

Authors Zhang M, Dong B, Lu M, Zheng M, Chen H, Ding J, Xu A, Xu Y

Received 6 July 2015

Accepted for publication 8 December 2015

Published 3 March 2016 Volume 2016:9 Pages 1123—1133

DOI https://doi.org/10.2147/OTT.S91879

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati


Min Zhang,1 Bing-bin Dong,2 Min Lu,1 Mei-juan Zheng,1 He Chen,1 Jing-zhen Ding,3 A-Man Xu,2 Yuan-hong Xu1

1Clinical Laboratory, 2Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China; 3Department of Cellular and Molecular Medicine, Howard Hughes Medical Institute, University of California at San Diego, La Jolla, CA, USA

Abstract: It has been previously reported that the deregulation of microRNAs in gastric cancer (GC) was correlated with the progression and prognosis. miR-429, a member of the miR-200 family, was previously shown to play an important role in human carcinomas. Our study shows that miR-429 is significantly downregulated in GC tissues compared with matched nontumor tissues. Overexpression of miR-429 in GC cells suppressed cell proliferation. Fascin-1 (FSCN1) was identified as one of the targets of miR-429 and knockdown of FSCN1 mimics the function of miR-429 overexpression. In conclusion, miR-429 acts as a tumor suppressor by targeting FSCN1, suggesting that miR-429 and FSCN1 can both be potential therapeutic targets of GC.

Keywords:
miR-429, gastric cancer, FSCN1, proliferation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]